CA2634301C - Biological surgical patch prepared from animal tissue - Google Patents
Biological surgical patch prepared from animal tissue Download PDFInfo
- Publication number
- CA2634301C CA2634301C CA2634301A CA2634301A CA2634301C CA 2634301 C CA2634301 C CA 2634301C CA 2634301 A CA2634301 A CA 2634301A CA 2634301 A CA2634301 A CA 2634301A CA 2634301 C CA2634301 C CA 2634301C
- Authority
- CA
- Canada
- Prior art keywords
- substrate
- patch
- antigens
- protein molecules
- active layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
Abstract
Disclosed herein is a biological surgical patch having minimal immune rejection with good biocompatibility, along with safe/reliable application thereof, and a method of preparation thereof.
The biological surgical patch comprises a substrate prepared from a natural animal tissue; the patch is made by a method that includes the steps of crosslinking and fixing the substrate, minimizing antigens from the substrate, tanning the substrate, and incorporating an active layer in the substrate.
Cross-linking and fixing may be accomplished by using an epoxy compound that has a hydrocarbon backbone, that is water-soluble, and which does not contain an ether or ester linkage in its backbone.
Reagents are used to block specific active groups in protein molecules of the substrate, in order to minimize the antigens therein. Tanning is achieved preferably by grafting polymers onto collagen molecules of the substrate. The active layer preferably comprises a polypeptide or glycosaminoglycan.
The biological surgical patch comprises a substrate prepared from a natural animal tissue; the patch is made by a method that includes the steps of crosslinking and fixing the substrate, minimizing antigens from the substrate, tanning the substrate, and incorporating an active layer in the substrate.
Cross-linking and fixing may be accomplished by using an epoxy compound that has a hydrocarbon backbone, that is water-soluble, and which does not contain an ether or ester linkage in its backbone.
Reagents are used to block specific active groups in protein molecules of the substrate, in order to minimize the antigens therein. Tanning is achieved preferably by grafting polymers onto collagen molecules of the substrate. The active layer preferably comprises a polypeptide or glycosaminoglycan.
Description
BIOLOGICAL SURGICAL PATCH PREPARED FROM ANIMAL TISSUE
BACKGROUND OF THE INVENTION
1. Field of the Invention The present invention relates to a medical prosthesis for human implantation, and in particular, to a surgical patch that is used for repairing tissues or organs during surgery.
BACKGROUND OF THE INVENTION
1. Field of the Invention The present invention relates to a medical prosthesis for human implantation, and in particular, to a surgical patch that is used for repairing tissues or organs during surgery.
2. Description of the Prior Art Repair of defective tissues and organs is often required in modern surgical techniques, for example, repair of dura mater, repair of defective pleura, repair of peritoneum, repair of hernial strain, repair of diaphragm, repair of blood vessels, repair of atrial septum, repair of pericardium, repair of kidneys, etc. There are many "surgical sticking patches" that are currently being provided to meet clinical demands. However, these products were first prepared with synthetic materials.
These synthetic materials utilized in preparing the surgical sticking patches include polypropylene, polyethylene, polyamide, Dacron resin, polytetrafluoroethylene, silicone gel, and carbon fiber, among others, which are foreign to the human body and that remain permanently in the repaired tissues. These materials often lead to non-bacterial inflammatory diseases due to physical irritation and complications caused by chronic rejective reaction.
Other patches have been prepared with absorbable synthetic materials such as polyglycolic acid (PGA), polylactic acid (PLA) and copolymer thereof (PGA-PLA). However, the rate of degradation of these materials is difficult to control to coincide with the rate of tissue recovery, so the efficacy is often uncertain due to rapid degradation. In addition, the degraded products can bring local acidity which affects normal healing of the repaired tissues.
Animal membrane tissues such as fascia and bovine pericardium have also been utilized in recent years through conventional processes including defatting, cell removal and fixation with glutaraldehyde, but elimination of antigens is hardly effective because cell removal is employed as the only means for eliminating antigens. Additionally, fixation of tissues with glutaraldehyde is achieved by crosslinking through acetalization, and glutaraldehyde is released during degradation, leaving residual toxicity and causing more potent cellular toxicity so that its growth in the inherent tissue becomes difficult, resulting in poor repair effect.
SUMMARY OF THE DISCLOSURE
According to an aspect of the present invention, there is provided a method for preparing a biological surgical patch comprising a substrate prepared from animal membrane tissue, said method comprising: crosslinking and fixing the substrate; minimizing the antigens from the substrate; tanning the substrate; and incorporating an active layer in the substrate.
According to another aspect of the present invention, there is provided a biological surgical patch comprising a substrate prepared from animal membrane tissue, wherein: the substrate is crosslinked; antigens are minimized from the substrate; collagen molecules of the substrate are grafted;
and the substrate has an active layer incorporated therein.
According to yet another aspect of the present invention, there is provided a biological surgical patch comprising a substrate prepared from animal membrane tissue made by a method comprising: crosslinking and fixing the substrate; minimizing the antigens from the substrate; tanning the substrate; and incorporating an active layer in the substrate.
It is an object of the present invention to provide a biological surgical patch having no immune rejection with good biocompatibility and safe/reliable application, and a method of preparation thereof.
la In order to accomplish the objects of the present invention, the present invention provides a biological surgical patch made by a method that includes the steps of providing a natural animal tissue that has a substrate, crosslinking and fixing the substrate, minimizing the antigens from the substrate, tanning the substrate, and incorporating an active layer in the substrate.
BRIEF DESCRIPTION OF THE DRA WINGS
FIG. 1 is a cross-sectional view of a surgical patch according to one embodiment of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following detailed description is of the best presently contemplated modes of carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of illustrating general principles of embodiments of the invention. The scope of the invention is best defined by the appended claims.
The present invention provides a biological surgical patch comprising a substrate prepared from animal membrane tissues, treated with crosslinked fixation with a non-aldehyde fixative, and then treated to minimize antigens.
Animal membrane tissues are easily degraded or decomposed by microorganisms, so that crosslinking and fixation with a fixative is required.
Conventionally, glutaraldehyde is utilized as a fixative, but glutaraldehyde produces toxic radicals. Aldehydes undergo crosslinking with proteins through the acetal reaction and toxic aldehydes are released when the crosslinked products are degraded, so that products fixed with an aldehyde have long-term residual toxicity. When non-aldehyde fixatives such as epoxides, diacyl diamides, diisocyanates, polyethylene glycol or carbodiimides are utilized as fixatives in place of aldehydes, this toxicity problem can be minimized or even eliminated. For example, when an epoxide is utilized to replace aldehyde-type fixatives, a ring-opening/crosslinking reaction occurs readily because epoxides are unstable, but the crosslinking product can be made very stable and not 3o easily degraded by controlling the reaction condition. It is slowly degraded into polypeptides and amino acids and absorbed only when tissue growth and regeneration begin to devour it by secreting kallikrein, fibrinolysin and glucocorticoid hormone to help collagenase in the degradation. Such kind of passive degradation and tissue regeneration are occurring synchronously which is beneficial to tissue regenerative repair while having no residual toxicity of aldehydes. According to modern immunological theory, the antigenicity of animal tissues stems mainly from active groups located at specific sites and in specific conformations, and these active groups include -OH, -NH2, -SH, etc. The specific conformations result mainly from some specific hydrogen bonding formed by spiral protein chains. The specific sites and conformations 4o are called antigen determinants. One or more active reagents (e.g., acid anhydrides, acyl chlorides, amides, epoxides, etc.) that react readily with these groups are utilized to bond with and block these groups when treating animal tissues so that the antigens can be effectively minimized or eliminated. Simultaneously, reagents with strong hydrogen bonding (e.g., guanidine compounds) are utilized to replace the hydrogen bonding that gives the specific configurations so that the configurations are altered and the antigenicity is effectively eliminated.
Tanning The present invention uses an additional cross-linking method and a protein grafting method as a tanning process to improve the mechanical strength and toughness of the tissue. In this regard, a piece of animal membrane tissue usually provides poor mechanical properties (after harvesting). As used herein, "mechanical properties"
means strength, toughness, rigidity and modulus. Both cross-linking and protein grafting can alter the mechanical properties of the tissue collagen (protein) matrix.
Although cross-linking and protein grafting are common methods that are used to improve the mechanical properties of high polymers, it is still important to carefully determine the selection of reagents as well as the reaction conditions because protein can often be denatured. The length, density and distribution of cross-linkage are properly designed to ensure the stability of the tissue material and mechanical property.
For example, the molecular chain length of the crosslinking agent determines the cross-linking length. A longer chain results in better material flexibility.
However, larger molecular chains are more difficult to penetrate into the collagen matrix. For example, when selecting an epoxy compound as the cross-linking agent, the molecular chain is preferably 4-8 hydrocarbons. The cross-linking density determines the cross-linking degree. Denser cross-linking results in better material stability, but denser cross-linking (especially when combined with a shorter molecular chain) can introduce a higher local stress in the material. A relatively uniform distribution of the cross-linking is ideal, but is usually difficult to obtain. Utilizing a lower concentration of the cross-linking solution, under a lower temperature, longer reaction duration, and repeating a few more times with the same reaction can often yield better results. As an example, when using an epoxy compound as the cross-linking agent as described in U.S. Patent No. 6,106,555, good material stability, good flexibility, toughness and strength can be obtained by picking 4-8 hydrocarbon atom chain, with a concentration of 0.1 to 2%, under 4 to 24 degrees Celcius, reaction for 3-10 days, and repeating 2 to 5 times.
The chemical reagents can be the same as those described herein for use with tissue fixation. The protein grafting process can further improve the tissue's mechanical strength, toughness, rigidity and modulus. Protein grafting requires a large amount of polymer chains so that the nature of the protein structure can be changed substantially.
Some high polymers can be grafted into collagen molecules by means of polycondensative primers. In order to avoid introducing hazardous subject matter into the human body, it is preferable to use biodegradable high polymers as the grafting agents, such as polyglycolic acid (PGA), polylactic acid (PLA) and others.
These biodegradable polymers can be metabolized in the host environment through a tracarboxylic acid cycle just like for carbohydrates or fat metabolism. After such an extensive protein modification, up to 25 kGy gamma ray sterilization can be applied without adversely affecting the mechanical property of the tissue material.
The total amount of protein grafting can be controlled optimally.
Method A method of preparing the biological surgical patches according to the present invention comprises the following steps, and uses animal membrane tissue as the 1o substrate:
1. Selection of materials and pretreatment: Fresh animal membrane tissues are collected and trimmed to remove excessive impurities and irregular parts.
Examples of animal membrane tissues that can be used include animal diaphragm, pleura, pericardium, omentum or intestinal membrane.
2. Alkaline treatment: The membrane tissues are soaked in an alkaline solution. The alkaline solution can be NaOH, KOH or Ca(OH)2 solution.
3. Defatting: Fats and fat-soluble impurities in the substrate are extracted with an organic solvent.
4. Crosslinking fixation: The collagen molecules in the substrate are 2 0 crosslinked and fixed with a non-aldehyde fixative, as described in greater detail hereinbelow.
These synthetic materials utilized in preparing the surgical sticking patches include polypropylene, polyethylene, polyamide, Dacron resin, polytetrafluoroethylene, silicone gel, and carbon fiber, among others, which are foreign to the human body and that remain permanently in the repaired tissues. These materials often lead to non-bacterial inflammatory diseases due to physical irritation and complications caused by chronic rejective reaction.
Other patches have been prepared with absorbable synthetic materials such as polyglycolic acid (PGA), polylactic acid (PLA) and copolymer thereof (PGA-PLA). However, the rate of degradation of these materials is difficult to control to coincide with the rate of tissue recovery, so the efficacy is often uncertain due to rapid degradation. In addition, the degraded products can bring local acidity which affects normal healing of the repaired tissues.
Animal membrane tissues such as fascia and bovine pericardium have also been utilized in recent years through conventional processes including defatting, cell removal and fixation with glutaraldehyde, but elimination of antigens is hardly effective because cell removal is employed as the only means for eliminating antigens. Additionally, fixation of tissues with glutaraldehyde is achieved by crosslinking through acetalization, and glutaraldehyde is released during degradation, leaving residual toxicity and causing more potent cellular toxicity so that its growth in the inherent tissue becomes difficult, resulting in poor repair effect.
SUMMARY OF THE DISCLOSURE
According to an aspect of the present invention, there is provided a method for preparing a biological surgical patch comprising a substrate prepared from animal membrane tissue, said method comprising: crosslinking and fixing the substrate; minimizing the antigens from the substrate; tanning the substrate; and incorporating an active layer in the substrate.
According to another aspect of the present invention, there is provided a biological surgical patch comprising a substrate prepared from animal membrane tissue, wherein: the substrate is crosslinked; antigens are minimized from the substrate; collagen molecules of the substrate are grafted;
and the substrate has an active layer incorporated therein.
According to yet another aspect of the present invention, there is provided a biological surgical patch comprising a substrate prepared from animal membrane tissue made by a method comprising: crosslinking and fixing the substrate; minimizing the antigens from the substrate; tanning the substrate; and incorporating an active layer in the substrate.
It is an object of the present invention to provide a biological surgical patch having no immune rejection with good biocompatibility and safe/reliable application, and a method of preparation thereof.
la In order to accomplish the objects of the present invention, the present invention provides a biological surgical patch made by a method that includes the steps of providing a natural animal tissue that has a substrate, crosslinking and fixing the substrate, minimizing the antigens from the substrate, tanning the substrate, and incorporating an active layer in the substrate.
BRIEF DESCRIPTION OF THE DRA WINGS
FIG. 1 is a cross-sectional view of a surgical patch according to one embodiment of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following detailed description is of the best presently contemplated modes of carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of illustrating general principles of embodiments of the invention. The scope of the invention is best defined by the appended claims.
The present invention provides a biological surgical patch comprising a substrate prepared from animal membrane tissues, treated with crosslinked fixation with a non-aldehyde fixative, and then treated to minimize antigens.
Animal membrane tissues are easily degraded or decomposed by microorganisms, so that crosslinking and fixation with a fixative is required.
Conventionally, glutaraldehyde is utilized as a fixative, but glutaraldehyde produces toxic radicals. Aldehydes undergo crosslinking with proteins through the acetal reaction and toxic aldehydes are released when the crosslinked products are degraded, so that products fixed with an aldehyde have long-term residual toxicity. When non-aldehyde fixatives such as epoxides, diacyl diamides, diisocyanates, polyethylene glycol or carbodiimides are utilized as fixatives in place of aldehydes, this toxicity problem can be minimized or even eliminated. For example, when an epoxide is utilized to replace aldehyde-type fixatives, a ring-opening/crosslinking reaction occurs readily because epoxides are unstable, but the crosslinking product can be made very stable and not 3o easily degraded by controlling the reaction condition. It is slowly degraded into polypeptides and amino acids and absorbed only when tissue growth and regeneration begin to devour it by secreting kallikrein, fibrinolysin and glucocorticoid hormone to help collagenase in the degradation. Such kind of passive degradation and tissue regeneration are occurring synchronously which is beneficial to tissue regenerative repair while having no residual toxicity of aldehydes. According to modern immunological theory, the antigenicity of animal tissues stems mainly from active groups located at specific sites and in specific conformations, and these active groups include -OH, -NH2, -SH, etc. The specific conformations result mainly from some specific hydrogen bonding formed by spiral protein chains. The specific sites and conformations 4o are called antigen determinants. One or more active reagents (e.g., acid anhydrides, acyl chlorides, amides, epoxides, etc.) that react readily with these groups are utilized to bond with and block these groups when treating animal tissues so that the antigens can be effectively minimized or eliminated. Simultaneously, reagents with strong hydrogen bonding (e.g., guanidine compounds) are utilized to replace the hydrogen bonding that gives the specific configurations so that the configurations are altered and the antigenicity is effectively eliminated.
Tanning The present invention uses an additional cross-linking method and a protein grafting method as a tanning process to improve the mechanical strength and toughness of the tissue. In this regard, a piece of animal membrane tissue usually provides poor mechanical properties (after harvesting). As used herein, "mechanical properties"
means strength, toughness, rigidity and modulus. Both cross-linking and protein grafting can alter the mechanical properties of the tissue collagen (protein) matrix.
Although cross-linking and protein grafting are common methods that are used to improve the mechanical properties of high polymers, it is still important to carefully determine the selection of reagents as well as the reaction conditions because protein can often be denatured. The length, density and distribution of cross-linkage are properly designed to ensure the stability of the tissue material and mechanical property.
For example, the molecular chain length of the crosslinking agent determines the cross-linking length. A longer chain results in better material flexibility.
However, larger molecular chains are more difficult to penetrate into the collagen matrix. For example, when selecting an epoxy compound as the cross-linking agent, the molecular chain is preferably 4-8 hydrocarbons. The cross-linking density determines the cross-linking degree. Denser cross-linking results in better material stability, but denser cross-linking (especially when combined with a shorter molecular chain) can introduce a higher local stress in the material. A relatively uniform distribution of the cross-linking is ideal, but is usually difficult to obtain. Utilizing a lower concentration of the cross-linking solution, under a lower temperature, longer reaction duration, and repeating a few more times with the same reaction can often yield better results. As an example, when using an epoxy compound as the cross-linking agent as described in U.S. Patent No. 6,106,555, good material stability, good flexibility, toughness and strength can be obtained by picking 4-8 hydrocarbon atom chain, with a concentration of 0.1 to 2%, under 4 to 24 degrees Celcius, reaction for 3-10 days, and repeating 2 to 5 times.
The chemical reagents can be the same as those described herein for use with tissue fixation. The protein grafting process can further improve the tissue's mechanical strength, toughness, rigidity and modulus. Protein grafting requires a large amount of polymer chains so that the nature of the protein structure can be changed substantially.
Some high polymers can be grafted into collagen molecules by means of polycondensative primers. In order to avoid introducing hazardous subject matter into the human body, it is preferable to use biodegradable high polymers as the grafting agents, such as polyglycolic acid (PGA), polylactic acid (PLA) and others.
These biodegradable polymers can be metabolized in the host environment through a tracarboxylic acid cycle just like for carbohydrates or fat metabolism. After such an extensive protein modification, up to 25 kGy gamma ray sterilization can be applied without adversely affecting the mechanical property of the tissue material.
The total amount of protein grafting can be controlled optimally.
Method A method of preparing the biological surgical patches according to the present invention comprises the following steps, and uses animal membrane tissue as the 1o substrate:
1. Selection of materials and pretreatment: Fresh animal membrane tissues are collected and trimmed to remove excessive impurities and irregular parts.
Examples of animal membrane tissues that can be used include animal diaphragm, pleura, pericardium, omentum or intestinal membrane.
2. Alkaline treatment: The membrane tissues are soaked in an alkaline solution. The alkaline solution can be NaOH, KOH or Ca(OH)2 solution.
3. Defatting: Fats and fat-soluble impurities in the substrate are extracted with an organic solvent.
4. Crosslinking fixation: The collagen molecules in the substrate are 2 0 crosslinked and fixed with a non-aldehyde fixative, as described in greater detail hereinbelow.
5. Minimizing antigens: An active reagent is utilized to block the specific active groups such as -OH ,-NH2, -SH, etc., in the proteins of the substrate, and a reagent with strong hydrogen bonding power is utilized to replace the specific hydrogen bonding in the spiral chains of the protein molecules in the substrate and alter its specific configuration.
6. Tanning process: First, the preformed polymers are produced from monomers by synthesis. Second, the substrate is dehydrated with alcohol.
Third, the preformed polymers are then grafted into collagen molecules by means of polycondensative primers. When using PGA as the grafting reagent, a small amount of glycolide may be used as the polycondensative primer. When using PLA as the grafting reagent, a small amount of lactide may be used as the polycondensative primer.
For example, using PLA as the protein grafting agent, the process could take 30-50 mg of lactide and dissolve it in 1000 ml of chloroform. 2-3 grams of triisobutyl aluminum can be added as the composite catalyst, and this solution can be stir-mixed for one to two hours under a temperature of 40-60 degrees Celcius. 100 ml of a 0.1 N NaOH
solution is then added and stir-mixed for 30-60 minutes to destroy the catalyst. Then take away the separated water layer (with catalyst) and have the preformed polymers ready.
Immerse the dehydrated substrate into the preformed polymer solution. Add 0.1 to 2g of lactide and 0.5 to 5g of proprionic anhydride as an initiation catalyst and then stir-mix for 2-4 hours under a temperature of 34 to 40 degrees Celcius. Take out the substrate and put it into chloroform to clean away the residual preformed polymers. After rinsing with saline, the substrate is then immersed into saline for 12 to 24 hours to recover the water content. The substrate is now ready for the next processing step.
Third, the preformed polymers are then grafted into collagen molecules by means of polycondensative primers. When using PGA as the grafting reagent, a small amount of glycolide may be used as the polycondensative primer. When using PLA as the grafting reagent, a small amount of lactide may be used as the polycondensative primer.
For example, using PLA as the protein grafting agent, the process could take 30-50 mg of lactide and dissolve it in 1000 ml of chloroform. 2-3 grams of triisobutyl aluminum can be added as the composite catalyst, and this solution can be stir-mixed for one to two hours under a temperature of 40-60 degrees Celcius. 100 ml of a 0.1 N NaOH
solution is then added and stir-mixed for 30-60 minutes to destroy the catalyst. Then take away the separated water layer (with catalyst) and have the preformed polymers ready.
Immerse the dehydrated substrate into the preformed polymer solution. Add 0.1 to 2g of lactide and 0.5 to 5g of proprionic anhydride as an initiation catalyst and then stir-mix for 2-4 hours under a temperature of 34 to 40 degrees Celcius. Take out the substrate and put it into chloroform to clean away the residual preformed polymers. After rinsing with saline, the substrate is then immersed into saline for 12 to 24 hours to recover the water content. The substrate is now ready for the next processing step.
7. Surface modification with active layer to induce activity: A process of modifying and activating the surface of the substrate, by coupling the substrate surface with active substances such as polypeptides or glycosaminoglycans which are capable of adhering to growth factors, to form an active surface layer, using a coupling agent. The coupling agent can be a diacyl diamide, diacid anhydride, diepoxide or other bifunctional reagents capable of carrying out condensation with -NH2, -OH and -COOH.
Fixative The fixative applied in step 4 of the above method can be a reagent that crosslinks easily with protein molecules and is one or two reagents selected from epoxides, diacyl diamides, diisocyanates, polyethylene glycol or carbodiimides. This fixative may be an epoxy compound that has a hydrocarbon backbone, that is water-soluble, and which does not contain an ether or ester linkage in its backbone. This fixative is described in U.S. Pat. No. 6,106,555. Examples include an epoxide, a diamide, a diisocyanate, a polyethylene glycol, or a carbodiimide, in that the epoxide may be a monocyclic epoxide, or a bicyclic epoxide, or it may be a low poly(epoxide) (such as low poly(ethylene oxide), poly(propylene oxide) or a glycidyl ether). The epoxide may be a monocyclic epoxide or a dicyclic epoiR-CH-CH2 O
C1cJ27CH-(CH2)n Gt1,CH2 where R-H, CnH2r 1_, n=0-10, and may also be a lower polyepoxide such as O O
polypropylene oxide.
Active Reagents [0031 ] The active reagents in step 5 of the above method may be low molecular weight organic acid anhydrides, acyl chlorides, acyl amides or epoxides, and the reagents having strong hydrogen bonding power are guanidine compounds.
Modification for Strength Improvement In step 6 above, the substrate is modified by strengthening it with proteins to prepare a strong substrate.
Because some membrane tissues lack the required mechanical strength for practical application, such as hernia repairing patches, and the mechanical strength is often reduced during biochemical treatment, appropriate grafting is conducted on collagen molecules, in that polyamide, polyamine, polyester polylactic acid or polyglycolic acid fragments are suitably grafted on the collagen molecules. The materials utilized are the prepolymers of these materials and the methods include polymer grafting methods such as condensation, induction and irradiation. This modification improves the mechanical strength and toughness of the substrate.
Active Layer [0035] The active layer in step 7 above is incorporated on the surface by coupling it with an active component such as a polypeptide or glycosaminoglycan. One example of the polypeptides is the polypeptide obtained from the condensation of 16 lysines (K16), glycine (G), arginine (R), asparagic acid (D), serine (S), proline (P) and cysteine (C), and the glycosaminoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, acetylheparin sulfate or keratan sulfate. These polypeptides or glycosaminoglycans exhibit a broad-spectrum adherence and enriching effect for growth factors or activate undifferentiated cells to perform oriented differentiation so that they are capable of exercising the function of inducing regenerative repair of organic tissues.
The present invention provides the following advantages. The original materials are animal membrane tissues comprising collagen as the main component which can be 1o degraded at a rate that coincides with the growth rate of tissue regeneration, and the products of degradation are 20 different amino acids or polypeptides that can be absorbed by the body, which are beneficial to the regenerative repair of the defective tissues. The surgical patches of the present invention exhibit no immune rejection and have good biocompatibility and can induce and promote tissue regeneration while having mechanical property that meets the mechanical requirements of the tissues for repair.
Example 1 As shown in FIG. 1, the biological surgical patch comprises (i) a substrate 1 prepared from porcine or bovine pericardium by crosslinking fixation with a non-aldehyde fixative, eliminating antigens and improving the strength with a protein, and (ii) active surface layers 2 formed by on both the top and bottom surfaces of substrate 1 by coupling an active component such as a specific polypeptide or glycosaminoglycan. One example of the polypeptides is the polypeptide obtained from the condensation of 16 lysines (K16), glycine (G), arginine (R), asparagic acid (D), serine (S), proline (P) and cysteine (C), and the glycosaminoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, acetylheparin sulfate or keratan sulfate.
The method of preparation of the biological surgical patch of the present invention includes the following steps, using porcine or bovine pericardium as the substrate:
1. Selection of materials and pretreatment: Fresh porcine or bovine pericardium are collected from slaughterhouses managed by professionals in accordance with regulations while contact with pollutants is avoided.
Preliminary sterilization is performed using a broad-spectrum antibacterial agent such as benzalkonium chloride, sodium azide and chlorhexidine and the impurities and irregular portions are removed and trimmed.
2. Alkaline treatment: Soaking of the substrate 1 in NaOH, KOH or Ca(OH)2 solution is conducted for several hours.
3. Defatting: Fats and fat-soluble impurities in the substrate 1 are extracted with an organic solvent such as chloroform, ethyl acetate, anhydrous alcohol or mixtures thereof.
4. Crosslinking fixation: The collagen molecules in the substrate 1 are crosslinked and fixed using epoxide or polyethylene glycol solution as a fixative.
5. Elimination of antigens: The specific active group, namely -OH or -NH2 or SH, in the proteins of the substrate 1 is blocked with an active reagent such as a small-molecule organic acid anhydride, acyl chloride, acyl amine and monocyclic oxide, and the specific hydrogen bonding in the spiral chains of the proteins in the substrate 1 is replaced by using a reagent such as a guanidine compound with strong hydrogen bonding.
6. Tanning process: Utilizing PLA as the grafting reagent, a small amount of lactide is used as the polycondensative primer.
7. Surface modification to induce activity: An active component such as a 1o specific polypeptide or glycosaminoglycan is coupled onto the surface of substrate 1 by using a coupling agent such as diacyldiamine or diacid anhydride or epoxide or other bifunctional reagents capable of carrying out condensation with -NH2, -OH and -COOH
groups to form the active surface layers 2 on the two surfaces of substrate 1.
Fixative The fixative applied in step 4 of the above method can be a reagent that crosslinks easily with protein molecules and is one or two reagents selected from epoxides, diacyl diamides, diisocyanates, polyethylene glycol or carbodiimides. This fixative may be an epoxy compound that has a hydrocarbon backbone, that is water-soluble, and which does not contain an ether or ester linkage in its backbone. This fixative is described in U.S. Pat. No. 6,106,555. Examples include an epoxide, a diamide, a diisocyanate, a polyethylene glycol, or a carbodiimide, in that the epoxide may be a monocyclic epoxide, or a bicyclic epoxide, or it may be a low poly(epoxide) (such as low poly(ethylene oxide), poly(propylene oxide) or a glycidyl ether). The epoxide may be a monocyclic epoxide or a dicyclic epoiR-CH-CH2 O
C1cJ27CH-(CH2)n Gt1,CH2 where R-H, CnH2r 1_, n=0-10, and may also be a lower polyepoxide such as O O
polypropylene oxide.
Active Reagents [0031 ] The active reagents in step 5 of the above method may be low molecular weight organic acid anhydrides, acyl chlorides, acyl amides or epoxides, and the reagents having strong hydrogen bonding power are guanidine compounds.
Modification for Strength Improvement In step 6 above, the substrate is modified by strengthening it with proteins to prepare a strong substrate.
Because some membrane tissues lack the required mechanical strength for practical application, such as hernia repairing patches, and the mechanical strength is often reduced during biochemical treatment, appropriate grafting is conducted on collagen molecules, in that polyamide, polyamine, polyester polylactic acid or polyglycolic acid fragments are suitably grafted on the collagen molecules. The materials utilized are the prepolymers of these materials and the methods include polymer grafting methods such as condensation, induction and irradiation. This modification improves the mechanical strength and toughness of the substrate.
Active Layer [0035] The active layer in step 7 above is incorporated on the surface by coupling it with an active component such as a polypeptide or glycosaminoglycan. One example of the polypeptides is the polypeptide obtained from the condensation of 16 lysines (K16), glycine (G), arginine (R), asparagic acid (D), serine (S), proline (P) and cysteine (C), and the glycosaminoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, acetylheparin sulfate or keratan sulfate. These polypeptides or glycosaminoglycans exhibit a broad-spectrum adherence and enriching effect for growth factors or activate undifferentiated cells to perform oriented differentiation so that they are capable of exercising the function of inducing regenerative repair of organic tissues.
The present invention provides the following advantages. The original materials are animal membrane tissues comprising collagen as the main component which can be 1o degraded at a rate that coincides with the growth rate of tissue regeneration, and the products of degradation are 20 different amino acids or polypeptides that can be absorbed by the body, which are beneficial to the regenerative repair of the defective tissues. The surgical patches of the present invention exhibit no immune rejection and have good biocompatibility and can induce and promote tissue regeneration while having mechanical property that meets the mechanical requirements of the tissues for repair.
Example 1 As shown in FIG. 1, the biological surgical patch comprises (i) a substrate 1 prepared from porcine or bovine pericardium by crosslinking fixation with a non-aldehyde fixative, eliminating antigens and improving the strength with a protein, and (ii) active surface layers 2 formed by on both the top and bottom surfaces of substrate 1 by coupling an active component such as a specific polypeptide or glycosaminoglycan. One example of the polypeptides is the polypeptide obtained from the condensation of 16 lysines (K16), glycine (G), arginine (R), asparagic acid (D), serine (S), proline (P) and cysteine (C), and the glycosaminoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, acetylheparin sulfate or keratan sulfate.
The method of preparation of the biological surgical patch of the present invention includes the following steps, using porcine or bovine pericardium as the substrate:
1. Selection of materials and pretreatment: Fresh porcine or bovine pericardium are collected from slaughterhouses managed by professionals in accordance with regulations while contact with pollutants is avoided.
Preliminary sterilization is performed using a broad-spectrum antibacterial agent such as benzalkonium chloride, sodium azide and chlorhexidine and the impurities and irregular portions are removed and trimmed.
2. Alkaline treatment: Soaking of the substrate 1 in NaOH, KOH or Ca(OH)2 solution is conducted for several hours.
3. Defatting: Fats and fat-soluble impurities in the substrate 1 are extracted with an organic solvent such as chloroform, ethyl acetate, anhydrous alcohol or mixtures thereof.
4. Crosslinking fixation: The collagen molecules in the substrate 1 are crosslinked and fixed using epoxide or polyethylene glycol solution as a fixative.
5. Elimination of antigens: The specific active group, namely -OH or -NH2 or SH, in the proteins of the substrate 1 is blocked with an active reagent such as a small-molecule organic acid anhydride, acyl chloride, acyl amine and monocyclic oxide, and the specific hydrogen bonding in the spiral chains of the proteins in the substrate 1 is replaced by using a reagent such as a guanidine compound with strong hydrogen bonding.
6. Tanning process: Utilizing PLA as the grafting reagent, a small amount of lactide is used as the polycondensative primer.
7. Surface modification to induce activity: An active component such as a 1o specific polypeptide or glycosaminoglycan is coupled onto the surface of substrate 1 by using a coupling agent such as diacyldiamine or diacid anhydride or epoxide or other bifunctional reagents capable of carrying out condensation with -NH2, -OH and -COOH
groups to form the active surface layers 2 on the two surfaces of substrate 1.
8. Packaging: Washing, packing and sealing while sterilizing by irradiating with Cobalt-60.
While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention.
While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention.
Claims (19)
1. A method for preparing a biological surgical patch comprising a substrate prepared from animal membrane tissue, said method comprising:
crosslinking and fixing the substrate;
minimizing antigens from the substrate;
tanning the substrate; and incorporating an active layer in the substrate.
crosslinking and fixing the substrate;
minimizing antigens from the substrate;
tanning the substrate; and incorporating an active layer in the substrate.
2. The method of claim 1, wherein the active layer comprises a polypeptide or glycosaminoglycan.
3. The method of claim 1 or 2, wherein cross-linking and fixing the substrate is accomplished using an epoxide, a diamide, a diisocyanate, or a carbodiimide.
4. The method of claim 1 or 2, wherein cross-linking and fixing the substrate is accomplished using an epoxy compound that has a hydrocarbon backbone; is water-soluble; and does not contain either an ether or ester linkage in the hydrocarbon backbone.
5. The method of any one of claims 1 to 4, wherein the substrate comprises protein molecules; the protein molecules comprise spiral chains; and minimizing the antigens from the substrate comprises:
utilizing a first reagent to block one or more antigen determinants of the substrate; and utilizing a second reagent with hydrogen bonding to replace hydrogen bonding in the spiral chains of the protein molecules in the substrate and alter its specific conformation.
utilizing a first reagent to block one or more antigen determinants of the substrate; and utilizing a second reagent with hydrogen bonding to replace hydrogen bonding in the spiral chains of the protein molecules in the substrate and alter its specific conformation.
6. The method of any one of claims 1 to 5, wherein the animal membrane tissue is pericardium.
7. The method of any one of claims 1 to 6, wherein the substrate comprises collagen molecules, and tanning the substrate comprises: producing polymers from monomers; and grafting the polymers onto the collagen molecules.
8 8. A biological surgical patch comprising a substrate prepared from animal membrane tissue, wherein: the substrate is crosslinked; antigens are minimized from the substrate;
collagen molecules of the substrate are grafted; and the substrate has an active layer incorporated therein.
collagen molecules of the substrate are grafted; and the substrate has an active layer incorporated therein.
9. The patch of claim 8, wherein the active layer includes a polypeptide or glycosaminoglycan.
10. The patch of claim 8 or 9, wherein the substrate is crosslinked by an epoxide, a diamide, a diisocyanate, or a carbodiimide.
11. The patch of claim 8 or 9, wherein the substrate is crosslinked by an epoxy compound that has a hydrocarbon backbone; is water-soluble, and does not contain either an ether or ester linkage in the hydrocarbon backbone.
12. The patch of claim any one of claims 8 to 11, wherein: the substrate comprises protein molecules; the protein molecules comprise spiral chains; the antigens are minimized from the substrate by a first reagent that blocks one or more antigen determinants of the substrate; and a second reagent with hydrogen bonding to replace hydrogen bonding in the spiral chains of the protein molecules in the substrate and alter its specific conformation.
13. The patch of any one of claims 8 to 12, wherein the animal membrane tissue is pericardium.
14. A biological surgical patch comprising a substrate prepared from animal membrane tissue made by a method comprising:
crosslinking and fixing the substrate;
minimizing antigens from the substrate;
tanning the substrate; and incorporating an active layer in the substrate.
crosslinking and fixing the substrate;
minimizing antigens from the substrate;
tanning the substrate; and incorporating an active layer in the substrate.
15. The patch of claim 14, wherein the active layer comprises a polypeptide or glycosaminoglycan.
16. The patch of claim 14 or 15, wherein the substrate is fixed by an epoxide, a diamide, a diisocyanate, or a carbodiimide.
17. The patch of claim 14 or 15, wherein the substrate is fixed by an epoxy compound that has a hydrocarbon backbone; is water-soluble; and does not contain either an ether or ester linkage in the hydrocarbon backbone.
18. The patch of claim any one of claims 14 to 17, wherein the substrate comprises protein molecules; the protein molecules comprise spiral chains; and the antigens are minimized from the substrate by a first reagent that blocks one or more antigen determinants of the substrate; and a second reagent with hydrogen bonding to replace hydrogen bonding in the spiral chains of the protein molecules in the substrate and alter its specific conformation.
19. The patch of any one of claims 14 to 18, wherein the animal membrane tissue is pericardium.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510120796.5 | 2005-12-20 | ||
| CN2005101207965A CN1986007B (en) | 2005-12-20 | 2005-12-20 | Biological surgical patch |
| PCT/CN2006/003419 WO2007071164A1 (en) | 2005-12-20 | 2006-12-15 | Biological surgical patch and method of making |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2634301A1 CA2634301A1 (en) | 2007-06-28 |
| CA2634301C true CA2634301C (en) | 2012-02-14 |
Family
ID=38174705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2634301A Active CA2634301C (en) | 2005-12-20 | 2006-12-15 | Biological surgical patch prepared from animal tissue |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8100970B2 (en) |
| EP (1) | EP1968659B1 (en) |
| JP (1) | JP5415078B2 (en) |
| CN (1) | CN1986007B (en) |
| AU (1) | AU2006329149B2 (en) |
| CA (1) | CA2634301C (en) |
| RU (1) | RU2438714C2 (en) |
| WO (1) | WO2007071164A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1986001B (en) * | 2005-12-20 | 2011-09-14 | 广东冠昊生物科技股份有限公司 | Biological wound-protecting film |
| CN1986006A (en) | 2005-12-20 | 2007-06-27 | 广州知光生物科技有限公司 | Biological nerve duct |
| CN101332316B (en) * | 2008-07-22 | 2012-12-26 | 广东冠昊生物科技股份有限公司 | Biotype nose bridge implantation body |
| US7544213B2 (en) * | 2006-09-12 | 2009-06-09 | Adams Jason P | Inflatable hernia patch |
| WO2008078166A2 (en) | 2006-12-22 | 2008-07-03 | Laboratoire Medidom S.A. | In situ system for intra-articular chondral and osseous tissue repair |
| CN101773419B (en) * | 2009-01-13 | 2013-08-21 | 樊昊 | Pelvic floor repairing patch |
| CN101480360B (en) * | 2009-01-22 | 2012-08-29 | 广东冠昊生物科技股份有限公司 | Mammary prostheses supporting device |
| CN102753105B (en) * | 2010-02-19 | 2015-09-30 | 生命细胞公司 | Stomach wall therapy equipment |
| CN104436305B (en) * | 2014-11-05 | 2017-01-11 | 暨南大学 | Cardiac muscle tonifying tablet taking acellular biological membrane as carrier as well as preparation method and application of cardiac muscle tonifying tablet |
| CN105935454A (en) * | 2015-09-18 | 2016-09-14 | 广州市美昊生物科技有限公司 | Decellularized matrix-source tissue engineering scaffold and preparation method and application thereof |
| CN105903080B (en) * | 2016-05-23 | 2019-04-02 | 苏州恒瑞迪生医疗科技有限公司 | A kind of breast sticking patch and preparation method thereof |
| RU183498U1 (en) * | 2018-03-01 | 2018-09-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения РФ | Artery wall defect closure |
| CN116440328A (en) * | 2022-01-14 | 2023-07-18 | 爱美客技术发展股份有限公司 | Regulation method of degradation period of acellular biological tissue material and application thereof |
| CN116440312A (en) * | 2022-01-14 | 2023-07-18 | 爱美客技术发展股份有限公司 | Medical material containing decellularized biological tissue material |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3974526A (en) | 1973-07-06 | 1976-08-17 | Dardik Irving I | Vascular prostheses and process for producing the same |
| DE2453363B2 (en) * | 1974-11-11 | 1976-08-26 | Solco Basel AG, Birsfelden (Schweiz) | METHOD OF MANUFACTURING HETEROLOGICAL ARTERIAL TRANSPLANTS |
| AU516741B2 (en) * | 1978-05-23 | 1981-06-18 | Bio Nova Neo Technics Pty. Ltd. | Vascular prostheses |
| US4378224A (en) * | 1980-09-19 | 1983-03-29 | Nimni Marcel E | Coating for bioprosthetic device and method of making same |
| US4481009A (en) * | 1982-05-13 | 1984-11-06 | American Hospital Supply Corporation | Polymer incorporation into implantable biological tissue to inhibit calcification |
| US5217492A (en) * | 1982-09-29 | 1993-06-08 | Bio-Metric Systems, Inc. | Biomolecule attachment to hydrophobic surfaces |
| US4597766A (en) * | 1984-10-26 | 1986-07-01 | American Hospital Supply Corporation | Implantable bioprosthetic tendons and ligaments |
| US4765335A (en) * | 1987-03-16 | 1988-08-23 | Intermar, Inc. | Aneurysm clip |
| JP2529112B2 (en) * | 1987-08-31 | 1996-08-28 | 株式会社 高研 | Biological valve |
| US5078744A (en) * | 1987-09-04 | 1992-01-07 | Bio-Products, Inc. | Method of using tendon/ligament substitutes composed of long, parallel, non-antigenic tendon/ligament fibers |
| US4793344A (en) * | 1987-11-02 | 1988-12-27 | Recore, Inc. | Method for preparing corneal donor tissue for refractive eye surgery |
| US5067962A (en) * | 1989-04-18 | 1991-11-26 | Baxter International Inc. | Bioprosthetic ligament |
| FR2649982B1 (en) * | 1989-07-20 | 1991-09-27 | Inst Nat Sante Rech Med | ARTIFICIAL BIOLOGICAL MEMBRANE |
| CA2066660C (en) * | 1989-09-15 | 2002-07-30 | Cary Reich | Method for achieving epithelialization of synthetic lenses |
| US5290217A (en) * | 1991-10-10 | 1994-03-01 | Earl K. Sipes | Method and apparatus for hernia repair |
| JP3532565B2 (en) * | 1991-12-31 | 2004-05-31 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Removable low melt viscosity acrylic pressure sensitive adhesive |
| WO1994017851A1 (en) * | 1993-02-08 | 1994-08-18 | Massachusetts Institute Of Technology | Bilayer composite hydrogels for corneal prostheses |
| US5447536A (en) * | 1994-02-17 | 1995-09-05 | Biomedical Design, Inc. | Method for fixation of biological tissue |
| US5549666A (en) * | 1994-09-02 | 1996-08-27 | Baxter International Inc. | Natural tissue valve prostheses having variably complaint leaflets |
| WO1996029937A1 (en) * | 1995-03-24 | 1996-10-03 | Organ, Inc. | Vessel and duct salvage device and method |
| US20020095218A1 (en) * | 1996-03-12 | 2002-07-18 | Carr Robert M. | Tissue repair fabric |
| US5711969A (en) * | 1995-04-07 | 1998-01-27 | Purdue Research Foundation | Large area submucosal tissue graft constructs |
| WO1996040001A1 (en) * | 1995-06-07 | 1996-12-19 | Baxter International Inc. | Externally supported tape reinforced vascular graft |
| US5984858A (en) * | 1995-06-07 | 1999-11-16 | Crosscart, Inc. | Meniscal xenografts |
| US5902338A (en) * | 1995-09-15 | 1999-05-11 | Crosscart, Inc. | Anterior cruciate ligament heterograft |
| US6458889B1 (en) * | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| US6666892B2 (en) * | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
| ES2213835T3 (en) * | 1996-09-16 | 2004-09-01 | Purdue Research Foundation | SUBMUCOSAL INTESTINAL FABRICS GRAFT FOR THE REPAIR OF NEUROLOGICAL FABRICS. |
| US6545042B2 (en) * | 1996-11-05 | 2003-04-08 | Gp Medical | Acellular biological material chemically treated with genipin |
| WO1998024385A1 (en) | 1996-12-06 | 1998-06-11 | Tapic International Co., Ltd. | Artificial blood vessel |
| US5993844A (en) | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
| US6117979A (en) * | 1997-08-18 | 2000-09-12 | Medtronic, Inc. | Process for making a bioprosthetic device and implants produced therefrom |
| US6482584B1 (en) * | 1998-11-13 | 2002-11-19 | Regeneration Technologies, Inc. | Cyclic implant perfusion cleaning and passivation process |
| US6008292A (en) * | 1997-12-02 | 1999-12-28 | Baxter International Inc. | Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials |
| DE19809121C1 (en) * | 1998-03-04 | 1999-08-12 | Aesculap Ag & Co Kg | Organ clip for aneurysm |
| MXPA00012063A (en) * | 1998-06-05 | 2003-04-22 | Organogenesis Inc | Bioengineered vascular graft support prostheses. |
| CN1313741A (en) | 1998-09-07 | 2001-09-19 | 清水庆彦 | Artificial blood vessel |
| US6106555A (en) * | 1998-12-15 | 2000-08-22 | Av Healing Llc | Method for tissue fixation |
| US6177514B1 (en) * | 1999-04-09 | 2001-01-23 | Sulzer Carbomedics Inc. | Blocked functional reagants for cross-linking biological tissues |
| WO2000064371A1 (en) * | 1999-04-27 | 2000-11-02 | The Children's Hospital Of Philadelphia | Stabilization of implantable bioprosthetic devices |
| US6312474B1 (en) * | 1999-09-15 | 2001-11-06 | Bio-Vascular, Inc. | Resorbable implant materials |
| CA2422852C (en) * | 2000-09-18 | 2012-06-26 | Organogenesis Inc. | Methods for treating a patient using a bioengineered flat sheet graft prostheses |
| EP1326544B1 (en) | 2000-10-17 | 2004-08-18 | Aesculap AG & Co. KG | Aneurysm clip |
| US7077851B2 (en) * | 2000-10-17 | 2006-07-18 | Aesculap Ag & Co. Kg | Aneurysm clip |
| US6974526B2 (en) * | 2001-05-01 | 2005-12-13 | Calibrant Biosystems, Inc. | Plastic microfluidics enabling two-dimensional protein separations in proteome analysis |
| CA2452040C (en) * | 2001-06-29 | 2011-03-22 | Cook Biotech Incorporated | Porous sponge matrix medical devices and methods |
| EP1416874A4 (en) * | 2001-07-16 | 2007-04-18 | Depuy Products Inc | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
| KR100514582B1 (en) * | 2001-09-05 | 2005-09-13 | 한스바이오메드 주식회사 | A Process for Preparing a Biomaterial for Tissue Repair |
| AU2003257179A1 (en) * | 2002-08-02 | 2004-02-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| US7273896B2 (en) * | 2003-04-10 | 2007-09-25 | Angiotech Pharmaceuticals (Us), Inc. | Compositions and methods of using a transient colorant |
| CN1259110C (en) | 2003-04-18 | 2006-06-14 | 四川大学华西医院 | Method and devices for preparing biology derivation material |
| CN1214821C (en) * | 2003-05-27 | 2005-08-17 | 重庆大学 | Preparing method for heteroossein base materials |
| CN1326502C (en) | 2003-08-07 | 2007-07-18 | 中山大学中山眼科中心 | Artificial tissue engineeing biological cornea |
| CA2542946A1 (en) * | 2003-10-28 | 2005-05-12 | Medtronic, Inc. | Methods of preparing crosslinked materials and bioprosthetic devices |
| US7955788B2 (en) * | 2003-10-30 | 2011-06-07 | Medtronic, Inc. | Bioprosthetic tissue preparation with synthetic hydrogels |
| US7615375B2 (en) * | 2003-12-18 | 2009-11-10 | Xerox Corporation | Osmotic reaction cell for monitoring biological and non-biological reactions |
| CN100333702C (en) | 2004-04-28 | 2007-08-29 | 浙江大学医学院附属邵逸夫医院 | Exogenous cornea substrate without cells and its preparation method and use |
| US7919112B2 (en) * | 2004-08-26 | 2011-04-05 | Pathak Holdings, Llc | Implantable tissue compositions and method |
| CN1985778B (en) * | 2005-12-20 | 2010-10-13 | 广东冠昊生物科技股份有限公司 | Artificial biological cornea |
| US20080195229A1 (en) * | 2007-02-09 | 2008-08-14 | Quijano Rodolfo C | Decellularized pericardial tissue |
-
2005
- 2005-12-20 CN CN2005101207965A patent/CN1986007B/en active Active
-
2006
- 2006-12-15 JP JP2008546073A patent/JP5415078B2/en active Active
- 2006-12-15 CA CA2634301A patent/CA2634301C/en active Active
- 2006-12-15 US US11/639,604 patent/US8100970B2/en active Active
- 2006-12-15 AU AU2006329149A patent/AU2006329149B2/en not_active Ceased
- 2006-12-15 RU RU2008127983/15A patent/RU2438714C2/en not_active IP Right Cessation
- 2006-12-15 EP EP06828333.2A patent/EP1968659B1/en active Active
- 2006-12-15 WO PCT/CN2006/003419 patent/WO2007071164A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006329149A1 (en) | 2007-06-28 |
| EP1968659B1 (en) | 2016-11-16 |
| EP1968659A4 (en) | 2012-07-04 |
| JP2009519789A (en) | 2009-05-21 |
| RU2438714C2 (en) | 2012-01-10 |
| US20070142847A1 (en) | 2007-06-21 |
| CA2634301A1 (en) | 2007-06-28 |
| WO2007071164A1 (en) | 2007-06-28 |
| AU2006329149B2 (en) | 2013-03-14 |
| EP1968659A1 (en) | 2008-09-17 |
| CN1986007B (en) | 2011-09-14 |
| CN1986007A (en) | 2007-06-27 |
| RU2008127983A (en) | 2010-01-27 |
| US8100970B2 (en) | 2012-01-24 |
| JP5415078B2 (en) | 2014-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2634301C (en) | Biological surgical patch prepared from animal tissue | |
| CA2634351C (en) | A biological artificial nerve guide comprising a tissue membrane with a spiral support and method of making | |
| US7674289B2 (en) | Biological artificial ligament and method of making | |
| CA2634323C (en) | Biological artificial cornea and method of making | |
| US8292799B2 (en) | Biological artificial blood vessel and method of making | |
| US7550152B2 (en) | Tissue graft scaffold made from cholecyst-derived extracellular matrix | |
| RU2438713C2 (en) | Biological wound covering and method of its production | |
| JP2009519789A5 (en) | ||
| AU6452398A (en) | Methods for actively binding heparin to biological and non- biological bioprosthetic material | |
| CN200951214Y (en) | Biological type surgical use patch | |
| CA2699129A1 (en) | Biological artificial ligament and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |